Aurobindo Pharma Ltd Q1 FY27 Earnings Analysis

- Specialty Injectables ex-Revlimid expected to grow at a similar double-digit rate starting FY27, with a base of approximately $480 million (Page 18). - US business targets $2 billion revenue milestone in near term, driven by portfolio expansion, acquisitions like Lannett (~$300 million incremental sales), and business development deals (Pages 6, 10). - European business achieved €1 billion revenue in FY26 with confident outlook for minimum double-digit growth in constant currency, supported by new product launches and China supply contributions (Pages 5, 8). - Biosimilars business aims to have 7-8 products marketed in Europe and growth markets plus 2-3 products in the US by 2030, targeting an inflection point in commercial momentum (Page 11). - CDMO business: First revenues expected from Unit-1 in 2028, full revenue ramp by 2031, with long-term ambition to evolve into a multi-customer CDMO (Pages 12, 23). - Overall, FY27 expected to be next phase of calibrated and profitable growth with EBITDA margins improving to north of 21% (Page 6).

- FY27 EBITDA margin is expected to sustain and progressively improve to north of 21%, reflecting scale, execution capabilities, and new business leverage. - Pen-G and 6-APA business turned EBITDA positive in the last quarter; overall FY26 loss was around ₹200 crores, expected to improve going forward. - China plant loss in FY26 is expected to convert into profitable EBITDA contribution in FY27. - Biosimilars business is in early innings; 7-8 products to be commercialized in Europe and growth markets by 2030, with 2-3 products potential approval in the US—leading to an inflection point by 2030. - U.S. formulations business targeting $2 billion revenue over the near term through base business expansion, new product launches, acquisitions (like Lannett), and in-licensing deals. - European business achieved €1 billion in FY26, targeting minimum double-digit growth going forward. - Overall outlook is for calibrated and profitable growth with stronger revenue visibility and improved profitability across businesses.

- Biosimilars segment has seen an overall investment of about $450 million (CapEx + OpEx) from July 2018 to date, including approvals and filings. - A greenfield CMO biological drug substance manufacturing facility (Unit-2) is under development with a planned investment of approximately $175 million. - Unit-1 of the Biological CDMO facility, with 60 KL capacity, is to be commissioned by end of 2026; revenues expected from 2028. - Unit-2 commissioning targeted for 2029; revenue to start around 2031. - Backward integration investments in Pen-G, 6-APA, and Amoxy continue to improve supply security and margin profile. - The company expects continued capital allocation to support scale-up in biologics, biosimilars, and CDMO businesses towards becoming a multi-customer CDMO by 2032.

The transcript on page 23 and surrounding pages does not mention any current or planned fundraising activities through debt or equity. Key points related to financial outlook include: - Focus on disciplined execution, operational excellence, and prudent capital allocation (Page 6). - No explicit discussion or guidance on raising funds via debt or equity. - Management discusses business growth, acquisitions, and organic expansion but no mention of new fundraising. - Acquisition of Lannett is underway, but funding or financing details are not stated. - Future growth initiatives like the CDMO unit and biosimilars are expected to be revenue generators; no mention of financing plans. In summary, the document provides no explicit updates or plans regarding new fundraising through debt or equity at present or in the near future.

The transcript provided on pages 6 to 23 of Aurobindo Pharma Limited's 22 May 2026 call does not explicitly mention current or expected order book or pending orders data in numerical terms. Key related points include: - The Company is advancing in biosimilars and biologics CMO strategies as long-term growth drivers. - The CDMO Unit-1 expected to start generating revenue from 2028; Unit-2 revenues from 2031. - Steady stream of revenues anticipated from the Merck/ MSD TheraNym contracts for commercial biological products. - The Pen-G unit has started external sales with over ₹100 crores worth of material sold last quarter. - The China facility is scaling steadily with increasing approvals and supplies into international markets, especially Europe. - The Europe business has achieved €1 billion milestone, with double-digit growth expected in constant currency. - US business targeting $2 billion revenue milestone over near term, with accretive acquisitions (like Lannett) contributing. No explicit order book or pending orders numbers disclosed in this section.